Literature DB >> 9182842

Influence of age on toremifene pharmacokinetics.

E A Sotaniemi1, M I Anttila.   

Abstract

Toremifene pharmacokinetics were compared in ten healthy young men (< 33 years) and elderly women (< 65 years). A single oral 120-mg dose of toremifene was given after an overnight fast and blood samples were collected over 28 days. Serum levels of the parent drug and the metabolites were determined; appropriate pharmacokinetic parameters were calculated and statistically evaluated. Toremifene peak concentrations (average 640 ng/ml) were achieved at 3.5 h. The area under the curve (AUC) and the apparent oral clearance were comparable in the young and elderly subjects. The half-life was prolonged (4.2 versus 7.2 days) and the apparent volume of distribution was increased (457 versus 627 1) in the elderly. The peak concentration of the main metabolite N-demethyltoremifene was lower (159 versus 233 ng/ml) and the half-life was prolonged (8.3 versus 19.1 days) in the elderly subjects, but the AUC values were comparable. The results suggest that toremifene is distributed more widely in the elderly but that its clearance is unaffected by age. It is concluded that the dosage requirement of the drug is unlikely to differ between young and elderly subjects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182842     DOI: 10.1007/s002800050645

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

Review 1.  Clinical pharmacokinetics of toremifene.

Authors:  T L Taras; G T Wurz; G R Linares; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 3.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.